TY - JOUR T1 - EPV208/#485 The clinical demand for pressurized intraperitoneal aerosol chemotherapy in south korea: an electronic survey-based study JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - A112 LP - A112 DO - 10.1136/ijgc-2021-IGCS.279 VL - 31 IS - Suppl 4 AU - EJ Lee AU - SJ Park AU - J Mun AU - H Paik AU - J Lee AU - A Seol AU - J Kim AU - N Lee AU - GW Yim AU - S-H Shim AU - HS Kim AU - S-J Chang Y1 - 2021/11/01 UR - http://ijgc.bmj.com/content/31/Suppl_4/A112.1.abstract N2 - Objectives Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is effective for treating solid tumors with peritoneal metastasis. However, PIPAC is not a standard treatment globally and is currently only used in the limited areas. Thus, we performed a survey of surgical oncologists related to PIPAC to evaluate the clinical desire for PIPAC in South Korea, one of the many countries where PIPAC has not yet been introduced.Methods We performed an online survey of Korean surgical oncologists between November and December 2019. The questionnaire consisted of 20 questions related to PIPAC, which were divided into comprehensive inquiry (5 questions), procedure inquiry (13 questions), and cost inquiry (2 questions).Results A total of 164 respondents answered the questionnaire. Among all respondents, 41.7–50% majoring in ovarian cancer, pseudomyxoma peritonei, and malignant mesothelioma preferred PIPAC for the curative treatment of primary diseases, whereas 32.7–33.3% majoring in colorectal and hepatobiliary cancers chose PIPAC for the palliative treatment of recurrent diseases. Moreover, 66.7–95.2% of the respondents considered PIPAC appropriate for the cancers the specialized in. About 70% expected a treatment response of more than 50% through the repeated implementation of PIPAC under general anesthesia. Respondents also considered grade 1 or 2 minor surgical complications an acceptable risk. Finally, respondents considered the reasonable costs to purchase and implement PIPAC once at between 1,000,000–5,000,000 KRW.Conclusions Although the treatment scope for applying PIPAC was different among Korean surgical oncologists, most of them expected relatively high tumor response rates with minor toxicities through the repeated implementation of PIPAC. ER -